Avoid late pipeline failures by identifying risks with early in vivo safety evaluation
Safety related issues and drug toxicity is a major reason why promising leads don't advance and candidates fail curing clinical development. The 'fail early' mantra in drug discovery was born out of the reality that late-stage failures result in significant setbacks and economic loss.
For early safety and toxicity assessment our Partner Lab, Pharmacology Discovery Services, is the go-to-provider with over 30 years of in vivo safety and early toxicity testing. Combined with our in vitro pharmacology and cell based in vitro toxicity assays services, the in vivo safety services from Pharmacology Discovery Services can provide a comprehensive risk profile for your leads at a stage when changes can still be made without a major impact to your project.
They offer a complete list of qualified safety related in vivo models to detect the most commonly observed adverse events in CNS, cardiovascular, respiratory, renal, metabolic, and gastrointestinal functions using a broad panel of industry-standard outcome measures to build a toxicokinetic (TK) profile. They can also provide specialized models, such as our emesis model, to address specific project needs.
Advantages of early, non-GLP safety screening with our Partner Lab, Pharmacology Discovery Services: